

1 **Title:** Incidence of Severe Acute Respiratory Syndrome Coronavirus-2 infection among
2 previously infected or vaccinated employees

3

4 **Authors:** Kojima N¹; Roshani A²; Brobeck M²; Baca A²; and Klausner JD³

5

6 ¹ Department of Medicine, University of California Los Angeles, Los Angeles, 90095

7 ² Curative Inc., San Dimas, CA

8 ³ Department of Population and Public Health Sciences, University of Southern
9 California, Keck School of Medicine, Los Angeles, 90033

10

11 **Keywords:** COVID-19; SARS-CoV-2; Incidence; Reinfection; Prior Infection;

12 Vaccination

13

14 **Abstract (Words 350)**

15 **Introduction:** The protective effect of previous infection versus vaccination is poorly
16 studied. Among a clinical laboratory that has been conducting routine workforce
17 screening since the beginning of the pandemic, we aimed to assess the relative risk of
18 Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection among
19 individuals who were SARS-CoV-2 naïve, previously infected, or vaccinated.

20 **Methods:** Using an electronic laboratory information system, employees were divided
21 into three groups: (1) SARS-CoV-2 naïve and unvaccinated, (2) previous SARS-CoV-2
22 infection, and (3) vaccinated. Person-days were measured from the date of the
23 employee first test and truncated at the end of the observation period. SARS-CoV-2
24 infection was defined as two positive SARS-CoV-2 PCR tests in a 30-day period.
25 Individuals with fewer than 14 days of follow up were excluded. Incidence estimates and
26 the 95% confidence intervals were calculated using the Poisson Exact equation. The
27 incidence rate ratio (IRR) was used as a measure of association between groups.
28 Analyses were performed on StataSE (StataCorp, College Station, TX).

29 **Results:** We identified 4313, 254 and 739 employee records for groups 1, 2, and 3,
30 respectively. The median age of employees was 29.0 years (interquartile range: 23.6,
31 39.9). During the observation period, 254, 0, and 4 infections were identified among
32 groups 1, 2, and 3, respectively. Group 1 had an incidence of 25.9 per 100 person-
33 years (95% CI: 22.8-29.3). Group 2 had an incidence of 0 per 100 person-years (95%
34 CI: 0-5.0). Group 3 had an incidence of 1.6 per 100 person-years (95% CI: 0.04-4.2).
35 The IRR of reinfection among those with previous infection compared to SARS-CoV-2
36 naïve was 0 (95% CI: 0-0.19). The IRR of those vaccinated compared to SARS-CoV-2

37 naïve was 0.06 (95% CI: 0.02-0.16). The IRR of those vaccinated compared to prior
38 SARS-CoV-2 was 0 (95% CI: 0-4.98).

39 **Conclusion:** Previous SARS-CoV-2 infection and vaccination for SARS-CoV-2 were
40 associated with decreased risk for infection or re-infection with SARS-CoV-2 in a
41 routinely screened workforce. There was no difference in the infection incidence between
42 vaccinated individuals and individuals with previous infection. Further research is
43 needed to determine whether our results are consistent with the emergence of new
44 SARS-CoV-2 variants.

45

46 **Main Text (930 words)**

47 **Introduction**

48 Prior reports have found lower rates of Severe Acute Respiratory Syndrome
49 Coronavirus-2 (SARS-CoV-2) infections among those with prior infection or
50 vaccination.^{1, 2} Although an association between vaccination and reduction of SARS-
51 CoV-2 incidence has been well described, how the incidence among individuals with
52 previous infection compares to vaccinated individuals remains unclear.

53

54 **Methods**

55 In March 2020, Curative, a SARS-CoV-2 testing company, began routinely screening its
56 workforce with an Food and Drug Administration-authorized SARS-CoV-2 polymerase
57 chain reaction (PCR)-based test.³ The workforce was screened daily. A standardized
58 employee testing database was implemented on 8 May 2020. On December 15, 2020,
59 vaccination with either the BNT162b2 or mRNA-1273 vaccines became available.
60 Routine screening has continued through July 2021.

61

62 The SARS-CoV-2 naïve, unvaccinated group was defined as any employee without
63 previous infection that tested from 8 May up to 15 December 2020 (when vaccination
64 became available). The previously infected, unvaccinated group was defined as any
65 employee with documented previous SARS-CoV-2 infection (at least 2 positive PCR
66 tests) between 8 May to 15 December 2020. The vaccinated group was defined as any
67 employee with documented completion of vaccination through 1 July 2021.

68

69 Person-days were measured from the first test date to last test date up to December
70 15th, 2020 for groups 1 and 2 and up to July 1, 2021 for group 3. We defined SARS-
71 CoV-2 infection as two positive PCR tests in a 30-day period. Individuals with fewer
72 than 14 days of follow up were excluded. Incidence in 100 person-years with 95%
73 confidence intervals (95% CIs) was calculated with the Poisson Exact equation. The
74 incidence rate ratio (IRR), the ratio of confirmed COVID-19 cases per 100 person-years
75 of follow up with 95% CIs, was used as a measure of association between groups.
76 Analyses were performed on StataSE (StataCorp, College Station, TX). The study of
77 de-identified electronic medical record data was determined by the Advarra institutional
78 review board (Pro00054560) to be exempt from review.

79

80 **Results**

81 We identified 4313, 254 and 739 employee records for the naïve and unvaccinated
82 group (Group 1), the previously infected and unvaccinated group (Group 2) and the
83 vaccinated without previous infection group (Group 3), respectively. The median age of
84 employees was 29.0 years (interquartile range: 23.6, 39.9). During the observation
85 period, 254, 0, and 4 SARS-CoV-2 incident infections were identified among Groups 1,
86 2, and 3, respectively. (Table).

87

88 The naïve, unvaccinated group had a SARS-CoV-2 incidence of 25.9 per 100 person-
89 years (95% CI: 22.8-29.3). The previously infected, unvaccinated group had an
90 incidence of 0 per 100 person-years (95% CI: 0-5.0). The vaccinated group had an
91 incidence of 1.6 per 100 person-years (95% CI: 0.04-4.2). The IRR of reinfection among

92 those with previous infection compared to those SARS-CoV-2 naïve was 0 (95% CI: 0-
93 0.19). The IRR of those vaccinated compared to those SARS-CoV-2 naïve was 0.06
94 (95% CI: 0.02-0.16). The IRR of those vaccinated compared to those previously SARS-
95 CoV-2 infected was 0 (95% CI: 0-4.98).

96

97 **Discussion**

98 In the workplace setting, we observed a lower incidence of SARS-CoV-2 infection
99 among those with previous SARS-CoV-2 infection or SARS-CoV-2 vaccination with
100 either the BNT162b2 or mRNA-1273 vaccines. Either prior infection or vaccination was
101 associated with a dramatic decreased risk for infection or re-infection with SARS-CoV-2.
102 There was no difference in the incidence of SARS-CoV-2 infection or re-infection between
103 individuals who were vaccinated and individuals with prior SARS-CoV-2 infection,
104 respectively.

105

106 Our findings are similar to other studies that compared the incidence of SARS-CoV-2
107 infection among those with prior SARS-CoV-2 infection and vaccination to unvaccinated
108 antibody seronegative individuals. In a study conducted in Oxfordshire, UK, researchers
109 reported that they found no differences in immunity induced by natural infection and
110 vaccination with the BNT162b2 or ChAdOx1 nCoV-19 vaccines among a cohort of
111 13,109 healthcare workers.⁴ Another group of researchers studying a group of 52,238
112 employees of the Cleveland Clinic Health System found that those with previous SARS-
113 CoV-2 infection and those who were vaccinated had lower rates of SARS-CoV-2
114 infection compared to those who were SARS-CoV-2 naïve and unvaccinated.⁵

115
116 After vaccination or natural infection, many mechanisms of immunity exist including
117 humoral and cellular immunity.⁶⁻⁸ It is known that SARS-CoV-2 infection induces specific
118 and durable T cell immunity against multiple SARS-CoV-2 spike (S) protein targets (or
119 epitopes) as well recognition of other SARS-CoV-2 proteins. The broad diversity of T-
120 cell viral recognition serves to enhance protection to SARS-CoV-2 variants,⁷ with
121 recognition of at least three SARS-CoV-2 variants (B.1.1.7 [U.K.], B.1.351 [South Africa],
122 and B.1.1.248 [Brazil]).⁹ Additionally, a memory B cell response to SARS-CoV-2 evolves
123 between 1.3 and 6.2 months after infection that is consistent with immune persistence.¹⁰

124
125 Our findings were limited by the observational nature of the study. It is possible, but
126 unlikely, that employees could have tested positive outside of the employee testing
127 program. In addition, because allocation to each exposure group was not random, there
128 might be differences between groups in the risk of repeat exposure over time. The study
129 was strengthened by the high incidence among those naïve and unvaccinated, the large
130 sample size and large number of person-years of follow up in each group.

131
132 **Conclusion**

133 We found a strong association between prior SARS-CoV-2 infection and vaccination for
134 SARS-CoV-2 with either BNT162b2 or mRNA-1273 and the reduced incidence of
135 SARS-CoV-2 when compared to those naïve and unvaccinated to SARS-CoV-2. The
136 was no difference in the incidence of SARS-CoV-2 between individuals who were
137 vaccinated and individuals with prior SARS-CoV-2 infection. Combined with prior

138 studies, our findings should provide increased confidence that those previously infected
139 are at very low risk for repeat infection. Further research is needed to determine
140 whether our results are consistent with the emergence of new SARS-CoV-2 variants.

141

142 **Declarations**

143 Declaration of competing interests

144 NK is a consultant for Curative. AR, MB, and AB are employed by Curative. JDK is an
145 independent consultant and serves as the Medical Director of Curative.

146

147 **Funding**

148 None

149

150 **Acknowledgements**

151 The staff at Curative Inc.

152 **References**

- 153 1. Qureshi AI, Baskett WI, Huang W, et al. Re-infection with SARS-CoV-2 in
154 Patients Undergoing Serial Laboratory Testing. *Clin Infect Dis*. Apr 25
155 2021;doi:10.1093/cid/ciab345
- 156 2. Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 Vaccine in a
157 Nationwide Mass Vaccination Setting. *N Engl J Med*. Apr 15 2021;384(15):1412-1423.
158 doi:10.1056/NEJMoa2101765
- 159 3. Kojima N, Turner F, Slepnev V, et al. Self-Collected Oral Fluid and Nasal Swab
160 Specimens Demonstrate Comparable Sensitivity to Clinician-Collected Nasopharyngeal
161 Swab Specimens for the Detection of SARS-CoV-2. *Clin Infect Dis*. Oct 19
162 2020;doi:10.1093/cid/ciaa1589
- 163 4. Lumley SF, Rodger G, Constantinides B, et al. An observational cohort study on
164 the incidence of SARS-CoV-2 infection and B.1.1.7 variant infection in healthcare
165 workers by antibody and vaccination status. *Clin Infect Dis*. 2021;
166 doi:10.1093/cid/ciab608
- 167 5. Shrestha NK, Burke PC, Nowacki AS, et al. Necessity of COVID-19 vaccination
168 in previously infected individuals. *medRxiv*. 2021; doi:10.1101/2021.06.01.21258176
- 169 6. Doshi P. Covid-19: Do many people have pre-existing immunity? *Bmj*. Sep 17
170 2020;370:m3563. doi:10.1136/bmj.m3563
- 171 7. Le Bert N, Tan AT, Kunasegaran K, et al. SARS-CoV-2-specific T cell immunity
172 in cases of COVID-19 and SARS, and uninfected controls. *Nature*. Aug
173 2020;584(7821):457-462. doi:10.1038/s41586-020-2550-z

- 174 8. Shrotri M, van Schalkwyk MCI, Post N, et al. T cell response to SARS-CoV-2
175 infection in humans: A systematic review. *PloS one*. 2021;16(1):e0245532.
176 doi:10.1371/journal.pone.0245532
- 177 9. Redd AD, Nardin A, Kared H, et al. CD8+ T cell responses in COVID-19
178 convalescent individuals target conserved epitopes from multiple prominent SARS-CoV-
179 2 circulating variants. *medRxiv*. Feb 12 2021;doi:10.1101/2021.02.11.21251585
- 180 10. Gaebler C, Wang Z, Lorenzi JCC, et al. Evolution of antibody immunity to SARS-
181 CoV-2. *Nature*. Mar 2021;591(7851):639-644. doi:10.1038/s41586-021-03207-w
182

183 **Table.** Incidence of SARS-CoV-2 infection among employees SARS-CoV-2 naïve, previously infected or vaccinated in a
 184 clinical laboratory workforce, 2020-2021

<u>SARS-CoV-2 Status</u>	<u>Cohort size</u>	<u>Number of infections</u>	<u>Follow up time (person-years)</u>	<u>Incidence per 100 PY (95% CI)*</u>
Naive	4313	254	979.7	25.9 (22.8-29.3)
Previously Infected	254	0	74.4	0 (0-5.0)
Fully Vaccinated	739	4	244.5	1.6 (0.04-4.2)

185 * PY = person-years, 95% Confidence Interval by Poisson Exact test